西峡县市场监管局关于2025年下半年药品监督抽查结果公示 | 序号 | 企业名称 | 企业类别 | 检查类型 | 检查结论 | 整改情况 | | --- | --- | --- | --- | --- | --- | | 1 | 河南张仲景大药房股份有限公司西峡莲花路店 | 零售药店 | 监督抽查 | 未发现问题 | / | | 2 | 河南张仲景大药房股份有限公司西峡莲花北路店 | 零售药店 | 监督抽查 | 未发现问题 | / | | 3 | 河南张仲景大药房股份有限公司西峡五里桥店 | 零售药店 | 监督抽查 | 未发现问题 | / | | 4 | 河南张仲景大药房股份有限公司西峡财富世家店 | 零售药店 | 监督抽查 | 未发现问题 | / | | 5 | 河南张仲景大药房股份有限公司西峡丁河镇店 | 零售药店 | 监督抽查 | 未发现问题 | / | | 6 | 西峡县康赛大药房有限公司建设西路店 | 零售药店 | 监督抽查 | 限期整改 | 已完成整改 | | 7 | 西峡县九九康大药房有限公司仲景路店 | 零售药店 | 监督抽查 | 未发现问题 | / | | 8 | 西峡县新兴大药房有限公司 ...

Group 1 - The core viewpoint emphasizes the importance of drug safety inspections in Urumqi City, Xinjiang, particularly during the holiday season, to ensure public health and safety [1] - The Urumqi Market Supervision Administration has conducted inspections on seven pharmacies, identifying three safety issues that require immediate rectification [1] - The inspections involved thorough checks of drug procurement channels, storage conditions, prescription drug sales management, and compliance with quality management standards [1] Group 2 - The Urumqi Market Supervision Administration plans to implement strict regulatory measures, combining special rectification efforts with daily supervision to enhance drug safety [2] - There is a commitment to a "zero tolerance" approach towards illegal activities in the pharmaceutical sector to safeguard drug quality during the holiday period [2] - The administration aims to continuously identify and address potential risks in the drug supply chain to protect public health [2]

Core Viewpoint - The National Development and Reform Commission (NDRC) has made significant progress in the market access barrier clearance action initiated in April, with over 3,800 documents reviewed and more than 2,300 regulations amended or abolished that were found to violate higher laws or lacked legal basis [1][2] Group 1 - The NDRC has identified and rectified 372 effective problem clues reported by various sectors and media, with 225 verified issues resolved across multiple industries, including second-hand car trading, pharmaceutical retail, construction, and transportation [2] - Specific examples of rectifications include the abolishment of local regulations that hindered fair market access for businesses, such as a local law requiring construction companies to be registered in the area, which has been rescinded [2] - The NDRC has established a collaborative mechanism involving 55 departments at national, provincial, municipal, and county levels to ensure timely and effective verification and rectification of reported issues [2]

Core Viewpoint - The National Development and Reform Commission (NDRC) has made significant progress in the cleanup and rectification of market access barriers, promoting the principle of "non-prohibition, immediate entry" [1][2]. Group 1: Market Access Barrier Cleanup - A total of over 38,000 documents were reviewed nationwide, resulting in the revision or abolition of more than 2,300 documents that either lacked legal basis or conflicted with higher laws [1]. - The NDRC addressed 372 effective problem clues reported by various sectors and media, verifying 225 of them, which involved multiple industries such as used car trading, pharmaceutical retail, construction, and transportation [1]. Group 2: Mechanism for Ongoing Improvement - The cleanup of market access barriers will transition into a regularized work mechanism, encouraging continuous feedback from society to optimize the market access environment [2]. - A collaborative working mechanism involving 55 departments at national, provincial, municipal, and county levels has been established to ensure timely and effective verification and rectification of reported issues [1].

进一步规范地方政府经济促进行为。 市场准入壁垒清理整治转为常态化 立破并举 今年7月中央财经委第六次会议就纵深推进全国统一大市场建设作了明确部署。有关部门出台实施了一 系列政策和改革举措，全国统一大市场建设"四梁八柱"已经基本建立，相关工作取得积极成效。 李超表示，在取得阶段性成效的同时，我们也深刻认识到，全国统一大市场建设仍然存在一些堵点卡 点，以及深层次的体制机制障碍。 具体表现在，市场准入方面，地方保护、市场分割、区域壁垒屡禁未绝。要素配置方面，市场配置资源 的决定性作用还没有充分发挥，各类要素协同配置效能还有待提高。地方政府行为尺度方面，部分地方 仍然存在招商引资行为不规范问题。监管执法方面，各地有关处罚事项的规定、标准仍然存在差 异，"同案不同罚"现象依然存在。此外，财税、统计、政绩考核等制度还需要根据全国统一大市场建设 的要求进一步调整完善。 李超表示，下一步，将坚持问题导向，坚持"立破并举"，把该"立"的立起来，把该"破"的破除掉，纵深 推进全国统一大市场建设。一方面，把有利于全国统一大市场建设的各项制度规则立起来。将推动出台 妨碍建设全国统一大市场事项清单，进一步规范地方政府经济促进行为；研究 ...

Core Viewpoint - The Yunnan Provincial Drug Administration has published five typical cases to strengthen the supervision of drug safety and combat illegal activities related to drugs, cosmetics, and medical devices, ensuring public health and safety. Group 1: Case Summaries - Case 1: A pharmacy in Changning purchased drugs from unqualified individuals, leading to the confiscation of illegal drugs and a fine totaling 250,000.00 yuan for the illegal purchase of drugs valued at 33,252.00 yuan [2][3] - Case 2: A gang led by Jiang Mouyan was involved in the production and sale of counterfeit drugs, resulting in the seizure of over 1.1 million suspected counterfeit drugs and a total case value exceeding 50 million yuan. The main offenders received prison sentences ranging from 1 year to 11 years and fines totaling 233,000 yuan [4][5] - Case 3: A traditional Chinese medicine clinic in Gejiu used expired drugs, leading to a fine of 20,000.00 yuan and the confiscation of expired drugs valued at 942.85 yuan [6][7][8] - Case 4: A hospital in Wenshan prepared traditional Chinese medicine without the necessary license, resulting in the confiscation of 381 bags of unlicensed medicine and a fine based on illegal gains of 28,600.00 yuan [9][10] - Case 5: A hair product store in Shangri-La sold unregistered cosmetics and failed to maintain proper purchase records, leading to a total fine of 5,105.00 yuan and the confiscation of 13 bottles of cosmetics [11][12]

Group 1 - The Ningxia Drug Administration conducted inspections on 31 pharmaceutical wholesale and retail companies, including notable firms like Lao Bai Xing, Hai Wang Bio, and Guo Yao Yi Zhi, focusing on organizational structure, quality management, computer systems, facilities, and drug procurement and sales [1][3] - The inspections revealed that Ningxia Tong Sheng Xiang Tong Ji Tang Pharmaceutical Co., Ltd. had 5 major defects and 5 general defects during its routine check from April 20 to 22, 2020, and was ordered to rectify these issues [1] - Ningxia Hai Wang Pharmaceutical Co., Ltd. was found to have 3 major defects and 1 general defect during its inspection on June 1 to 2, 2020, and was also instructed to make corrections [1] Group 2 - Ningxia Guo Da Pharmacy Chain Co., Ltd. had 1 major defect and 2 general defects during its inspection on June 15 to 16, 2020, and was required to rectify the issues [2] - Ningxia Tong Sheng Xiang Tong Ji Tang Pharmaceutical Co., Ltd. was established on June 29, 2017, with a registered capital of 23.8 million RMB, and is primarily owned by Lanzhou Hui Ren Tang Pharmaceutical Chain Co., Ltd., which holds a 92% stake [3] - Lao Bai Xing Pharmacy, a significant player in the retail pharmaceutical sector, was founded on December 1, 2005, with a registered capital of 292 million RMB, and is listed on the Shanghai Stock Exchange since April 23, 2015 [3] Group 3 - Ningxia Hai Wang Pharmaceutical Co., Ltd. was founded on March 15, 2002, with a registered capital of 10 million RMB, and is primarily owned by Henan Hai Wang Pharmaceutical Group Co., Ltd., which holds a 70% stake [4] - Shenzhen Hai Wang Bioengineering Co., Ltd., established on December 13, 1992, has a registered capital of 2.763 billion RMB and was listed on the Shenzhen Stock Exchange on December 18, 1998 [4] - The Hai Wang Group, founded in 1989, focuses on the pharmaceutical and health industry, with a sales scale of approximately 77.4 billion RMB in 2019 and a brand value of 91.568 billion RMB in 2020 [4] Group 4 - Ningxia Guo Da Pharmacy Chain Co., Ltd. was established on November 17, 2008, with a registered capital of 70 million RMB, and is primarily owned by Guo Yao Holding Guo Da Pharmacy Co., Ltd., which holds a 70% stake [5] - Guo Yao Yi Zhi, the parent company of Guo Da Pharmacy, is a comprehensive pharmaceutical listed company under China National Pharmaceutical Group, holding a 60% stake in Guo Yao Holding [5][6] - Guo Yao Yi Zhi was founded on August 2, 1986, with a registered capital of 428 million RMB, and was listed on the Shenzhen Stock Exchange on August 9, 1993 [6]

长期以来，市市场监督管理局高度重视家庭过期药品处理难题，出台《镇江市家庭过期药品回收管 理工作指南》，推动家庭过期药品定点回收、集中销毁工作走向"常态化、制度化、规范化"。截至目 前，全市已设立890家定点回收点，全面覆盖各板块及镇（街道），实现"群众家门口就能回收"的便捷 服务，极大降低了市民参与过期药品回收的门槛。 熊青海介绍，市场监管部门将持续加大宣传力度，积极倡导"按需购药、安全用药、规范弃药"理 念，不断提升群众的药品安全意识与环保意识；同时，将动员更多药品零售企业加入回收体系，进一步 完善回收网络布局，打造更方便快捷、规范有序的家庭过期药品回收处置格局。（孙宁 记者 朱婕 见习 记者 丁星） 12月25日，市市场监督管理局联合各市、区市场监管部门，开展2025年度家庭过期药品集中销毁活 动，守护公众用药安全与生态环境安全。 活动现场，回收的2.2万余盒家庭过期药品整齐收纳于专用纸箱中，等待由生态环境部门授权的危 险废物专业处理机构进行规范化无害化处置。整个销毁过程严格遵循安全、规范、环保的原则，从源头 杜绝过期药品重新流入市场、危害公众健康的风险。 "我们已建立起定点回收、统一转运、专业销毁的全链 ...

证券日报网讯12月26日，一心堂（002727）在互动平台回答投资者提问时表示，公司密切关注并严格遵 循《互联网平台价格行为规则》等政策导向，始终坚持聚焦药品零售主业，核心战略在于持续提升专业 药事服务能力和顾客体验。对于线上渠道，公司以顾客需求为中心，不断优化"一心到家"与第三方平台 在内的多渠道服务矩阵，致力于为消费者提供更优服务，实现健康可持续发展。 ...

Core Viewpoint - The announcement reveals that the controlling shareholder, Lao Bai Xi Medicine Group, has pledged 14 million shares of Lao Bai Xi Pharmacy, which raises concerns about the company's financial stability and stock performance [1] Share Pledge Situation - The total number of shares pledged by the controlling shareholder amounts to 114 million, representing 63.25% of their holdings and 15.04% of the company's total share capital [1][2] - The pledge is intended to meet the operational needs of the medicine group, which claims to have the ability to repay the funds, with repayment sources including dividends from the listed company and self-raised funds [2][3] Future Pledge and Reduction Plans - In the next six months, 12.35 million shares are set to mature, accounting for 6.84% of the controlling shareholder's holdings and 1.63% of the company's total shares, with a corresponding financing amount of 100 million [3] - The medicine group plans to reduce its holdings by 18.11 million shares between June 20 and July 30, 2025, at a price range of 17.60 to 21.55 yuan per share, totaling approximately 341 million [4] Financial Performance - Recent financial results show that the company experienced a revenue decline of 0.36% year-on-year in 2024, with a net profit drop of 44.13% [5] - For the first three quarters of 2025, both revenue and net profit continued to decline, with decreases of 1% and 16.11%, respectively [5] - The company's stock price has fallen over 70% from its peak of 53.14 yuan per share in 2020, closing at 15.26 yuan per share with a total market capitalization of 11.58 billion [5]